Dec. 8 at 6:42 PM
Ernexa Therapeutics reported promising preclinical data at the American Society of Hematology’s annual meeting. Its lead cell therapy candidate, ERNA-101, showed the ability to reprogram suppressive tumor environments into active immune states, demonstrating potential against both solid and blood cancers.
In an ovarian cancer model, the company’s engineered IL-7/IL-15-secreting iMSC cells significantly boosted immune cell infiltration and improved survival, with cytokine production levels around 20 times higher than previously seen with engineered T-cell approaches.
CEO Sanjeev Luther said the findings validate Ernexa’s platform, supporting the idea that iPSC-derived MSCs can become potent immunomodulators. The study with MD Anderson showed tumors shifting from “cold” immune-excluded states to highly inflamed “hot” environments required for modern immunotherapy responses.
$ERNA